Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer

Wenjie Liu, Yi Cui, Wen Ren, Joseph Maria Kumar Irudayaraj

Research output: Contribution to journalArticle

Abstract

Hormone-dependent gene expression involves dynamic and orchestrated regulation of epigenome leading to a cancerous state. Estrogen receptor (ER)-positive breast cancer rely on chromatin remodeling and association with epigenetic factors in inducing ER-dependent oncogenesis and thus cell over-proliferation. The mechanistic differences between epigenetic regulation and hormone signaling provide an avenue for combination therapy of ER-positive breast cancer. We hypothesized that epigenetic biomarkers within single nucleosome proximity of ER-dependent genes could serve as potential therapeutic targets. We described here a Fluorescence lifetime imaging-based Förster resonance energy transfer (FLIM-FRET) methodology for biomarker screening that could facilitate combination therapy based on our study. We screened 11 epigenetic-related markers which include oxidative forms of DNA methylation, histone modifications, and methyl-binding domain proteins. Among them, we identified H4K12acetylation (H4K12ac) and H3K27 acetylation (H3K27ac) as potential epigenetic therapeutic targets. When histone acetyltransferase inhibitor targeting H4K12ac and H3K27ac was combined with tamoxifen, an enhanced therapeutic outcome was observed against ER-positive breast cancer both in vitro and in vivo. Together, we demonstrate a single molecule approach as an effective screening tool for devising targeted epigenetic therapy.

Original languageEnglish (US)
Article number16
JournalClinical epigenetics
Volume11
Issue number1
DOIs
StatePublished - Jan 30 2019

Fingerprint

Optical Imaging
Energy Transfer
Epigenomics
Estrogen Receptors
Biomarkers
Breast Neoplasms
Acetylation
Therapeutics
Histone Code
Hormones
Histone Acetyltransferases
Chromatin Assembly and Disassembly
Nucleosomes
DNA Methylation
Tamoxifen
Carrier Proteins
Carcinogenesis
Cell Proliferation
Gene Expression
Genes

Keywords

  • Anacardic acid
  • Breast cancer
  • Combination therapy
  • Epigenetic markers
  • Fluorescence lifetime
  • Förster resonance energy transfer
  • Histone acetylation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Developmental Biology
  • Genetics(clinical)

Cite this

Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer. / Liu, Wenjie; Cui, Yi; Ren, Wen; Irudayaraj, Joseph Maria Kumar.

In: Clinical epigenetics, Vol. 11, No. 1, 16, 30.01.2019.

Research output: Contribution to journalArticle

@article{1558722e61dd496ea29bced2bcb4fa7e,
title = "Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer",
abstract = "Hormone-dependent gene expression involves dynamic and orchestrated regulation of epigenome leading to a cancerous state. Estrogen receptor (ER)-positive breast cancer rely on chromatin remodeling and association with epigenetic factors in inducing ER-dependent oncogenesis and thus cell over-proliferation. The mechanistic differences between epigenetic regulation and hormone signaling provide an avenue for combination therapy of ER-positive breast cancer. We hypothesized that epigenetic biomarkers within single nucleosome proximity of ER-dependent genes could serve as potential therapeutic targets. We described here a Fluorescence lifetime imaging-based F{\"o}rster resonance energy transfer (FLIM-FRET) methodology for biomarker screening that could facilitate combination therapy based on our study. We screened 11 epigenetic-related markers which include oxidative forms of DNA methylation, histone modifications, and methyl-binding domain proteins. Among them, we identified H4K12acetylation (H4K12ac) and H3K27 acetylation (H3K27ac) as potential epigenetic therapeutic targets. When histone acetyltransferase inhibitor targeting H4K12ac and H3K27ac was combined with tamoxifen, an enhanced therapeutic outcome was observed against ER-positive breast cancer both in vitro and in vivo. Together, we demonstrate a single molecule approach as an effective screening tool for devising targeted epigenetic therapy.",
keywords = "Anacardic acid, Breast cancer, Combination therapy, Epigenetic markers, Fluorescence lifetime, F{\"o}rster resonance energy transfer, Histone acetylation",
author = "Wenjie Liu and Yi Cui and Wen Ren and Irudayaraj, {Joseph Maria Kumar}",
year = "2019",
month = "1",
day = "30",
doi = "10.1186/s13148-019-0620-6",
language = "English (US)",
volume = "11",
journal = "Clinical Epigenetics",
issn = "1868-7075",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer

AU - Liu, Wenjie

AU - Cui, Yi

AU - Ren, Wen

AU - Irudayaraj, Joseph Maria Kumar

PY - 2019/1/30

Y1 - 2019/1/30

N2 - Hormone-dependent gene expression involves dynamic and orchestrated regulation of epigenome leading to a cancerous state. Estrogen receptor (ER)-positive breast cancer rely on chromatin remodeling and association with epigenetic factors in inducing ER-dependent oncogenesis and thus cell over-proliferation. The mechanistic differences between epigenetic regulation and hormone signaling provide an avenue for combination therapy of ER-positive breast cancer. We hypothesized that epigenetic biomarkers within single nucleosome proximity of ER-dependent genes could serve as potential therapeutic targets. We described here a Fluorescence lifetime imaging-based Förster resonance energy transfer (FLIM-FRET) methodology for biomarker screening that could facilitate combination therapy based on our study. We screened 11 epigenetic-related markers which include oxidative forms of DNA methylation, histone modifications, and methyl-binding domain proteins. Among them, we identified H4K12acetylation (H4K12ac) and H3K27 acetylation (H3K27ac) as potential epigenetic therapeutic targets. When histone acetyltransferase inhibitor targeting H4K12ac and H3K27ac was combined with tamoxifen, an enhanced therapeutic outcome was observed against ER-positive breast cancer both in vitro and in vivo. Together, we demonstrate a single molecule approach as an effective screening tool for devising targeted epigenetic therapy.

AB - Hormone-dependent gene expression involves dynamic and orchestrated regulation of epigenome leading to a cancerous state. Estrogen receptor (ER)-positive breast cancer rely on chromatin remodeling and association with epigenetic factors in inducing ER-dependent oncogenesis and thus cell over-proliferation. The mechanistic differences between epigenetic regulation and hormone signaling provide an avenue for combination therapy of ER-positive breast cancer. We hypothesized that epigenetic biomarkers within single nucleosome proximity of ER-dependent genes could serve as potential therapeutic targets. We described here a Fluorescence lifetime imaging-based Förster resonance energy transfer (FLIM-FRET) methodology for biomarker screening that could facilitate combination therapy based on our study. We screened 11 epigenetic-related markers which include oxidative forms of DNA methylation, histone modifications, and methyl-binding domain proteins. Among them, we identified H4K12acetylation (H4K12ac) and H3K27 acetylation (H3K27ac) as potential epigenetic therapeutic targets. When histone acetyltransferase inhibitor targeting H4K12ac and H3K27ac was combined with tamoxifen, an enhanced therapeutic outcome was observed against ER-positive breast cancer both in vitro and in vivo. Together, we demonstrate a single molecule approach as an effective screening tool for devising targeted epigenetic therapy.

KW - Anacardic acid

KW - Breast cancer

KW - Combination therapy

KW - Epigenetic markers

KW - Fluorescence lifetime

KW - Förster resonance energy transfer

KW - Histone acetylation

UR - http://www.scopus.com/inward/record.url?scp=85060846314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060846314&partnerID=8YFLogxK

U2 - 10.1186/s13148-019-0620-6

DO - 10.1186/s13148-019-0620-6

M3 - Article

C2 - 30700309

AN - SCOPUS:85060846314

VL - 11

JO - Clinical Epigenetics

JF - Clinical Epigenetics

SN - 1868-7075

IS - 1

M1 - 16

ER -